Acta Med. 2003, 46: 163-170

https://doi.org/10.14712/18059694.2019.27

A Study of Potential Toxic Effects After Repeated 10-Week Administration of a New Iron Chelator – Salicylaldehyde Isonicotinoyl Hydrazone (SIH) to Rabbits

Ivona Klimtováa, Tomáš Šimůneka, Yvona Mazurováb, Jana Kaplanovác, Martin Štěrbad, Radomír Hrdinaa, Vladimír Geršld, Michaela Adamcováe, Přemysl Poňkaf

aCharles University in Prague, Faculty of Pharmacy in Hradec Králové, Department of Pharmacology and Toxicology, Hradec Králové, Czech Republic
bCharles University in Prague, Faculty of Medicine in Hradec Králové, Department of Histology and Embryology, Hradec Králové, Czech Republic
cCharles University in Prague, Faculty of Medicine in Hradec Králové, Department of Paediatrics, Hradec Králové, Czech Republic
dCharles University in Prague, Faculty of Medicine in Hradec Králové, Department of Pharmacology, Hradec Králové, Czech Republic
eCharles University in Prague, Faculty of Medicine in Hradec Králové, Department of Physiology, Hradec Králové, Czech Republic
fMcGill University, Department of Physiology and Medicine, Montreal, Quebec, Canada

Received February 1, 2003
Accepted August 1, 2003

References

1. Barker E, Vitolo M, Webb J. Iron chelation by pyridoxal isonicotinoyl hydrazone and analogues in hepatocytes in culture. Biochem Pharmacol 1983; 34:298–302.
2. Besarab A, Jarrell BE, Hirsch S, Carabasi RA, Cressman MD, Green P. Use of the isolated perfused kidney model to assess the acute pharmacologic effects of cyclosporine and its vehicle, cremophor EL. Transplantation 1987; 44:195–201. <https://doi.org/10.1097/00007890-198708000-00005>
3. Dorr TR. Pharmacology and toxicology of Cremophor EL diluent. Ann Pharmacother 1994; 28(suppl 5):S11–S14.
4. Faa G, Crisponi G. Iron chelating agents in clinical practice. Coord Chem Rev 1999; 184:291–310. <https://doi.org/10.1016/S0010-8545(99)00056-9>
5. Ganong WF. Review of medical physiology. 19th edition. New York: Lange Medical Books, 1997:542.
6. Golenser J, Domb A, Teomim D. The treatment of animal models of malaria with iron chelators by use of a novel polymeric device for slow drug release. J Pharmacol Exper Therap 1997; 281:1127–35.
7. Hardman JG, Limbird LE, eds. Goodman&Gilman’s The pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill, 2001:698.
8. Hermes-Lima M, Santos NCF, Yan J, Andrews M, Schulman HM, Ponka P. EPR spin trapping and 2–deoxyribose degradation studies of the effect of pyridoxal isonicotinoyl hydrazone (PIH) on. OH formation by the Fenton reaction. Bioch Bioph Acta 1999; 1426:475–82. <https://doi.org/10.1016/S0304-4165(98)00167-6>
9. Horackova M, Ponka P, Byczko Z. The antioxidant effects of a novel iron chelator salicylaldehyde isonicotinoyl hydrazone in the prevention of H2O2 injury in adult cardiomyocytes. Cardiovasc Res 2000; 47:529–36. <https://doi.org/10.1016/S0008-6363(00)00088-2>
10. Klimtová I, Šimůnek T, Geršl V et al. Biochemical and haematological changes following reapeated pyridoxal isonicotinoyl hydrazone administration in rabbits. Biomarkers Environ 2001; 4(suppl 1):70–2.
11. Kraus AL, Weisbroth SH, Flatt RE, Brewer N. Biology and diseases of rabbits. In: Fox JG, Cohen BJ, Loew FM, eds. Laboratory animal medicine. Orlando: Academic Press, 1984:212–3.
12. Lieu PT, Heiskala M, Peterson PA, Yang Y. The roles of iron in health and disease. Mol Asp Med 2001; 22:1–87 <https://doi.org/10.1016/S0098-2997(00)00006-6>
13. Ponka P, Borová J, Neuwirt J, Fuchs O, Nečas E. A study of intracellular iron metabolism using pyridoxal isonicotinoyl hydrazone and other synthetic chelating agents. Bioch Biophys Acta 1979; 586:278–97. <https://doi.org/10.1016/0304-4165(79)90100-4>
14. Pye MP, Black M, Cobbe SM. Comparison of in vivo and in vitro haemodynamic function in experimental heart failure: use of echocardiography. Cardiovasc Res 1996; 31:873–81. <https://doi.org/10.1016/S0008-6363(96)00051-X>
15. Racek J et al. Klinická biochemie. 1. ed. Praha: Galen, 1999:80.
16. Richardson DR, Ponka P. Development of iron chelators to treat iron overload disease and their use as experimental tools to probe intracellular iron metabolism. Am J Hematol 1998; 58:299–305. <https://doi.org/10.1002/(SICI)1096-8652(199808)58:4<299::AID-AJH9>3.0.CO;2-L>
17. Richardson DR, Ponka P. Pyridoxal isonicotinoyl hydrazone and its analogs: Potential orally effective iron-chelating agents for the treatment of iron overload disease. J Lab Clin Med 1998; 131:306–14. <https://doi.org/10.1016/S0022-2143(98)90180-9>
18. Schulman HM, Hermes-Lima M, Wang E-M, Ponka P. In vitro antioxidant properties of the iron chelator pyridoxal isonicotinoyl hydrazone and some of its analogs. Redox Report 1996; 1:373–8. <https://doi.org/10.1080/13510002.1995.11747014>
19. Šimůnek T, Klimtová I, Geršl V et al. Effects of 10–week pyridoxal isonicotinoyl hydrazone administration on selected organ systems in rabbits (abstract). Acta Med (Hradec Králové) 2001; 44:64.
20. Šimůnek T, Klimtová I, Hrdina R et al. The effects of repeated administration of pyridoxal isonicotinoyl hydrazone on cardiovascular system in rabbits. Biomarkers Environ 2001; 4(suppl 1):70–2.
21. Sookvanichsilp N, Nakornchai S, Weerapradist W. Toxicological study of pyridoxal isonicotinoyl hydrazone: acute and subchronic toxicity. Drug Chem Toxicol 1991; 14:395–403. <https://doi.org/10.3109/01480549109011641>
22. Thiel G, Hermle M, Brunner FP. Acutely impaired renal function during intravenous administration of cyclosporine A: a cremophore side-effects. Clin Nephrol 1986; 25(suppl 1):S40–2.
23. Thliveris JA, Yatscoff RW, Lukowski MP, Copeland KR, Jeffery JR, Murphy GF. Chronic cislosporin nephrotoxicity: A rabbit model. Neph 1991; 57:470–6. <https://doi.org/10.1159/000186351>
24. Tsafack A, Loyevsky M, Ponka P, Cabantchik ZI. Mode of action of iron (III) chelators as antimalarials. IV. Potentiation of desferal action by benzoyl and isonicotinoyl hydrazone derivatives. J Lab Clin Med 1996; 127:574–82. <https://doi.org/10.1016/S0022-2143(96)90148-1>
25. Zanninelli G, Glickstein H, Breuer W et al. Chelation and mobilization of cellular iron by different classes of chelators. Mol Pharmacol 1997; 51:842–52. <https://doi.org/10.1124/mol.51.5.842>
front cover

ISSN 1211-4286 (Print) ISSN 1805-9694 (Online)

Open access journal

Archive